References
±, tumor, NMIBC
ADVERSE REACTIONS, TUMOR, ADVERSE REACTION
Human TLR ligand screening—OncoTheradRepresentative ultrasonography, cystoscopy, and photomicrographs of the urinary bladder before OncoTheradRepresentative ultrasonography, cystoscopy, and photomicrographs of the urinary bladder after OncoTheradOccurrence of some type of adverse reaction according to the degree of intensity.Representative immunolabeling of antigens in the urinary bladder before (Representative immunolabeling of antigens in the urinary bladder before (Representative immunoblots and semiquantitative determination of CX3CR1 protein levels. Representative protein profiles grouped from five patients per sample pool: before (pools 1, 2, 3, 4) and after (pools 1′, 2′, 3′, 4′) OncoTheradOncoTheradPatients’ baseline demographics and general features (Descriptive measures of quantitative variables (number of relapses, relapse-free survival, and response duration) and categorical variables (histological grade and pathological complete response) within the 24-month follow-up of patients treated with OncoTheradHistological grade, tumor size, and tumor focality assessment before (BCG and/or intravesical chemotherapy) and after OncoTherad* Statistical significance.Adverse reactions in patients with NMIBC who were subjected to OncoTheradMean ± standard deviation of total immunoreactivity (%) observed for different antigens, both before and after OncoTheradValues followed by different letters on the same line point out significant differences between groups (